Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The launch of Sarah Cannon Research UK and research developments at ASCO 2010

2010 ASCO Annual Meeting

Published: 22 Jul 2010

Views: 8038

Rating:

Save

Dr Jeffrey Infante - Sarah Cannon Research Institute, USA

Dr Infante discusses the work the Sarah Cannon Research Institute does and the benefits the launch of the UK programme will bring. He discusses the research the institute is presenting at ASCO 2010 and outlines the findings of his research into the MEK 1/2 inhibitor GSK1120212.

Categories:
Drug development

Related Videos

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

Linvoseltamab induces deep and durable responses in patients with relapsed or...

Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA

$Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma ( Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA )$

Autovaccination with the intratumoral viral mimic poly-ICLC makes a cold tumour...

Dr Sujit Nair - Icahn School of Medicine at Mount Sina, New York, USA

Autovaccination with the intratumoral viral mimic poly-ICLC makes a cold tumour hot in prostate cancer ( Dr Sujit Nair - Icahn School of Medicine at Mount Sina, New York, USA )

Avelumab combined with regorafenib shows improved outcome in solid tumours with...

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising...

Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium

Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC ( Prof Bertrand Tombal - Université Catholique de Louvain, Brussels, Belgium )

Blood test may identify patients with non-small cell lung cancer subtype who...

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial...

Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype ( Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA )

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective...

Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC ( Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

More from ecancer